20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Design Therapeutics Inc (DSGN) operates in the BIOTECHNOLOGY industry and is headquartered in Carlsbad, United States with about 55 employees. Its market capitalization is roughly $766 million. In the fiscal year ended 2025-12-31, DSGN reported $0M in revenue and ($70M) in net income.
Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States.
Interactive charts & full statements →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $1M |
| Gross Profit | — | ($1M) | ($1M) | ($1M) | $0M | $0M | $0M | $0M |
| Gross Margin % | — | — | — | — | — | — | -2212.4% | -0.1% |
| Operating Income (EBIT) | ($79M) | ($79M) | ($62M) | ($78M) | ($68M) | ($36M) | ($9M) | ($2M) |
| Operating Margin % | — | — | — | — | — | — | -3785840.7% | -228.8% |
| Net Income | ($71M) | ($70M) | ($50M) | ($67M) | ($59M) | ($36M) | ($8M) | ($2M) |
| Net Margin % | — | — | — | — | — | — | -3663716.8% | -245.4% |
| EBITDA | ($72M) | ($69M) | ($49M) | ($66M) | ($67M) | ($35M) | ($8M) | ($2M) |
| Earnings Per Share (EPS) | $-1.19 | $-1.22 | $-0.88 | $-1.19 | $-1.05 | $-0.77 | $-0.30 | $-0.08 |
| Shares Outstanding (M) | 63M | 57M | 57M | 56M | 56M | 46M | 27M | 27M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | $1M | $0M |
| Gross Profit | $0M | — | $15M | ($15M) | $0M | $0M | $0M | $0M |
| Gross Margin % | — | — | — | — | — | — | 50.0% | — |
| Operating Income (EBIT) | ($22M) | ($20M) | ($18M) | ($19M) | ($22M) | ($20M) | ($17M) | ($16M) |
| Operating Margin % | — | — | — | — | — | — | -2839.1% | — |
| Net Income | ($20M) | ($18M) | ($16M) | ($17M) | ($19M) | ($18M) | ($14M) | ($13M) |
| Net Margin % | — | — | — | — | — | — | -2321.6% | — |
| EBITDA | ($22M) | ($17M) | ($16M) | ($17M) | ($19M) | ($18M) | ($14M) | ($13M) |
| Earnings Per Share (EPS) | $-0.32 | $-0.29 | $-0.28 | $-0.30 | $-0.34 | $-0.31 | $-0.24 | $-0.23 |
| Shares Outstanding (M) | 63M | 61M | 57M | 57M | 57M | 57M | 57M | 57M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($55M) | ($54M) | ($43M) | ($59M) | ($51M) | ($29M) | ($9M) | $0M |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $1M | $2M | $0M | $0M |
| Free Cash Flow (FCF) | ($55M) | ($55M) | ($43M) | ($59M) | ($52M) | ($31M) | ($9M) | $0M |
| FCF Margin % | — | — | — | — | — | — | -3869469.0% | -25.8% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($16M) | ($16M) | ($12M) | ($11M) | ($14M) | ($17M) | ($10M) | ($10M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($16M) | ($16M) | ($12M) | ($11M) | ($15M) | ($17M) | ($10M) | ($10M) |
| FCF Margin % | — | — | — | — | — | — | -1676.9% | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $215M | $226M | $252M | $290M | $341M | $391M | $37M | $0M |
| Cash & Cash Equivalents | $13M | $17M | $23M | $21M | $26M | $299M | $2M | $0M |
| Total Liabilities | $13M | $14M | $10M | $12M | $14M | $8M | $48M | $4M |
| Total Debt (Short + Long-Term) | $0M | $1M | $1M | $1M | $1M | $0M | $0M | $1M |
| Total Shareholders' Equity | $202M | $213M | $242M | $278M | $327M | $382M | ($11M) | ($4M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive DSGN viewer.
About TickerBase · Data methodology & sources · Privacy · Terms